95 filings
Page 3 of 5
6-K
t1zctu8mtm84c7k3g6
30 Nov 21
ERYTECH Secures US Patent Directed to Sequential Use of Methioninase & Asparaginase against Solid Tumors
10:32am
6-K
cesl7xxt
16 Nov 21
Current report (foreign)
2:22pm
6-K
ox75ai
25 Oct 21
ERYTECH Announces Results from TRYbeCA-1 Phase 3
10:59am
6-K
fmy2v03pa4xqigk0
5 Oct 21
ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
12:34pm
6-K
nv3nj16gx8ueejz
21 Sep 21
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021
9:42am
6-K
zkfn6cse4gnky wbje
20 Sep 21
I.Certification of the Person Responsible for the Half-year Financial Report
1:37pm
6-K
mower06gy54bbeco
30 Jul 21
ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL
10:09am
6-K
yoa1xrre5ioh
26 Jul 21
Current report (foreign)
11:47am
6-K
y52c64
29 Jun 21
Current report (foreign)
8:18am
6-K
qvmlq0p4syf6u983
26 May 21
Live webcast of the Shareholders’ Meeting
9:55am
6-K
lyd071kdmx gt8qa
7 May 21
ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021
6:13am
6-K
d54y2ebw vjk
3 May 21
ERYTECH Announces $30.0 Million
5:20pm
6-K
bmqtrosdn
3 May 21
ERYTECH Reports Cash Balance at End of Q1 2021
6:07am
6-K
ye8y0weydmz w4j1d3
21 Apr 21
ERYTECH Requested a Pre-BLA Meeting with the FDA
8:01am
6-K
j93plosae3gqu9omp4z
19 Apr 21
ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of
9:48am
6-K
s6utbw05gu53
9 Mar 21
ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2020
9:55am
6-K
5ah9dk0y
8 Feb 21
ERYTECH Announces TRYbeCA-1 Phase 3 Trial
9:15am
6-K
w46j745 hd8tvya3cnp
27 Jan 21
ERYTECH Highlights 2021 Milestones
10:17am
6-K
xpv js51jzvww
15 Jan 21
ERYTECH Announces First Patient Enrolled in Eryaspase in First-Line Pancreatic Cancer
12:35pm
6-K
omjgsjnkm rl
15 Dec 20
ERYTECH Completes Enrollment in TRYbeCA-1
8:16am